期刊文献+

表达FLT1-CAR的Jurkat细胞的筛选及其对VEGF的趋向性 被引量:1

Screening of Jurkat cells expressing FLT1-CAR and their chemotaxis to VEGF
下载PDF
导出
摘要 目的:通过慢病毒介导获得表达针对血管内皮细胞生长因子受体1(vascular endothelial growth factor receptor 1,VEGFR1/FLT1)的嵌合抗原受体(chimeric antigen receptor,CAR)的Jurkat细胞,探讨其对VEGF的趋向性。方法:合成针对VEGFR1的CAR(FLT1-CAR),构建重组慢病毒载体LV-gn-FLT1-CAR,并感染Jurkat细胞;经G418筛选得到稳定转染细胞株;PCR及流式细胞术检测细胞株中FLT1-CAR mRNA及蛋白的表达,Transwell法检测细胞株对VEGF的趋化效果。结果:重组慢病毒LV-gn-FLT1-CAR成功构建;FLT1-CAR成功整合到Jurkat细胞中并稳定表达FLT1-CAR蛋白。筛选的细胞株Jurkatgn-FLT1-CAR-1、Jurkat-gn-FLT1-CAR-2对VEGF有显著趋化效果,100 ng/ml VEGF处理后,Jurkat-gn-FLT1-CAR-1细胞趋化数为(62±8)个,显著高于对照组Jurkat趋化细胞数的(18±5)个(P<0.01)。结论:成功筛选到稳定表达FLT1-CAR的Jurkat细胞克隆,其对VEGF有明显的趋向作用。 Objective:To construct Jurkat cells expressing chimeric antigen receptor (CAR) of vascular endothelial growth factor receptor 1 (VEGFR1/FLT1) using lentivirus and to investigate their chemotaxis to VEGF. Methods: The CAR targeting VEGFR1 was synthetized, and the recombinant lentiviral vector named LV-gn-FLT1-CAR was constructed and infected into Jurkat cells. Stable infected cell stains were obtained through G418 screening. The expressions of FLT1-CAR mRNA and protein in the stable infected cell stains were detected by PCR and flow cytometry. The chemotaxis of selected cell strains toward VEGF was detected by Transwell assay. Results: Recombinant lentivirus LV-gn-FLT1-CAR was successfully constructed. FLT1-CAR was successfully integrated into Jurkat cells and FLT1-CAR protein was stably expressed. The selected cell strains, Jurkat-gn-FLT1CAR-1 and Jurkat-gn-FLT1CAR-2, showed obvious chemotaxis to VEGF. In a VEGF concentration of 100 ng/ml, Jurkat-gn-FLT1-CAR-1 cell chemotactic number was (62±8),which was significantly higher than that of the control group Jurkat cells (18±5) (P〈0.01). Conclusion: Jurkat cell strains stably express FLT1-CAR are successfully obtained, which have a distinct chemotaxis to VEGF.
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2013年第5期559-564,共6页 Chinese Journal of Cancer Biotherapy
基金 国家科技部重大专项基金资助项目(No.2012ZX0002014-005) 国家自然科学基金面上项目(No.81071850)~~
关键词 血管内皮细胞生长因子 CXC趋化因子受体3 嵌合抗原受体 JURKAT细胞 趋化作用 vascular endothelial growth factor chemokine (C-X-C motif) receptor 3(CXCR3) chimeric antigen receptor Jurkat cell chemotaxis
  • 相关文献

参考文献21

  • 1Romeo C, Seed B. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptidcs [ J ]. Cell, 1991, 64 (5) : 1037-1046.
  • 2Roberts MR, Qin 1,, Zhang Dct al. Targeting of human immunod- eficiency vires-infected cells by CD8 + T lymplu'ytes armed with universal T-cell receptors [ J ]. Blood, 1994, 84 ( 9 ) : 2878- 2889.
  • 3Borghaei H, Smith MR, Campbcll KS. lmmunotherapy of cancer [J]. Eur J Pharmacol, 2009, 625(1/3) : 41-54.
  • 4Sadelain M, Brentjens R, Rivire I. The promise and potential pitfalls of chimeric antigen receptors [ J ]. Curr Opin Immunol, 2009, 21(2): 215-223.
  • 5Chicaybam L, Sodr AL, Bonamino M. Chimeric antigen receptors in cancer immuno-gene therapy Current status and future direc- tions [J]. Int RevImmunol, 2011, 30(5/6): 294-311.
  • 6王艺,赵颖颖,韩双印.基于嵌合抗原受体修饰T细胞的肿瘤免疫治疗新策略[J].中国肿瘤生物治疗杂志,2013,20(4):383-390. 被引量:9
  • 7Rosenberg SA, Dudley ME. Adoptive cell therapy for the treat- ment of patients with metastatic melanoma [ J ]. Curt" Opin hnmu- nol, 2009, 21 (2): 233-240.
  • 8Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia [ J 1. N Engl J Med, 2011, 365(8) : 723-733.
  • 9Richmond A, Yang J, Su Y. The good and the bad of chemo- kines/chemokine receptors in melanoma [J]. Pigment Cell Mela- noma Res, 2009, 22(2) : 175-186.
  • 10Lacotte S, Brun S, Muller S, et al. CXCR3, inflammation, and autoimmune diseases [ J]. Ann N Y Acad Sci, 2009, 1173: 310- 317.

二级参考文献50

  • 1张瑞萍,云琳,陆斌,彭玲,周倩,王浩,郭亚军.嵌合T细胞受体的构建及其在T淋巴细胞表面的表达和体外抗肿瘤功能的检测[J].中华实验外科杂志,2006,23(5):609-611. 被引量:3
  • 2Schreiber RD, Old U, Smyth MJ. Cancer immunoediting: In-tegrating immunity ’ s roles in cancer suppression and promotion[J]. Science,2011,331(6024) : 1565-1570.
  • 3Cheadle EJ,Sheard V,Hombach AA, et al. Chimeric antigen re-ceptors for T-cell based therapy [ J]. Methods Mol Biol, 2012,907: 645-666.
  • 4Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell trans-fer: A clinical path to effective cancer immunotherapy [ J] . NatRev Cancer, 2008, 8(4) : 299-308.
  • 5Gattinoni L, Lugli E, Ji Y, et al. A human memory T cell subsetwith stem cell-like properties [ J]. Nat Med,2011,17 (10 ):1290-1297.
  • 6Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cellreceptor chimeric molecules as functional receptors with antibody-type specificity [ J]. Proc Natl Acad Sci U S A, 1989, 86(24):10024-10028.
  • 7Ahmed N, Ratnayake M, Savoldo B,et al. Regression of experi-mental medulloblastoma following transfer of HE R2-specific Tcells [J]. Cancer Res, 2007, 67(12) : 5957-5964.
  • 8Chmielewski M, Hahn 0,Rappl G, et al. T cells that target car-cinoembryonic antigen eradicate orthotopic pancreatic carcinomaswithout inducing autoimmune colitis in mice [ J]. Gastroenterolo-gy, 2012, 143(4) :1095-1107.
  • 9Guest RD, Hawkins RE,Kirillova N,et al. The role of extracel-lular spacer regions in the optimal design of chimeric immune re-ceptors :Evaluation of four different scFvs and antigens [ J]. JImmunother, 2005,28(3) : 203-211.
  • 10Bridgeman JS, Hawkins RE, Bagley S, et al. The optimal antigenresponse of chimeric antigen receptors harboring the CD3zetatransmembrane domain is dependent upon incorporation of the re-ceptor into the endogenous TCR/CD3 complex [ J]. J Immunol,2010, 184(12) : 6938-6949.

共引文献8

同被引文献12

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部